All In Biotech

Drug Trial Radar · NCT02737371

Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects

F901318 - A Phase I, Double-Blind, Placebo Controlled, Multiple Ascending Oral Dose Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects

Last checked: Nov 19, 2026Latest source record: May 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

May 2016

Primary completion

May 22, 2017

Study completion May 22, 2017

Sponsor

Lead sponsor
F2G LtdIndustry
Sponsor type
Industry
Collaborators
SimbecRresearch Ltd.
First posted
Apr 13, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Double blind, placebo controlled, ascending multiple (10) oral dose, sequential group study. Twenty-four subjects will complete the study in 3 cohorts (Groups A to C), each group consisting of 8 subjects. Each cohort will consist of 4 male and 4 female subjects. Each subject will be dosed for 10 days and will be on study for approximately 7 weeks. Each subject will participate in one treatment cohort only, residing at the Clinical Research Unit (CRU) from Day -1 (the day before dosing) to Day 15 (120 hours post the last dose). The dose will range between 2 and 10 mg/kg daily, given as either a single daily dose or as two doses divided over the 24-hour dosing period. All subjects will return for a post-study visit 8 to 10 days after the last dose of study medication. Cohorts will be dosed at least at 3 weekly intervals. There will be a review of the safety and pharmacokinetic data of each cohort prior to each dose escalation.

Conditions

  • Invasive Aspergillosis

Interventions

  • F901318 Dose level A oralDrug

    Adverse events days 1-10

  • Placebo dose level A oralDrug

    Placebo adverse events days 1-10

  • F901318 Dose level B oralDrug

    F901318 adverse events days 1-10

  • Placebo dose level B oralDrug

    Placebo adverse events days 1-10

  • F901318 Dose level C oralDrug

    F901318 adverse events days 1-10

  • Placebo Dose level C oralDrug

    Placebo adverse events days 1-10

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events [Safety and TolerabilityTime frame: 10 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Simbec Research Ltd

    Merthyr Tydfil, Glamorgan, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.